We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Bioorthogonal Palladium-Labile Prodrugs for Site-Specific Anticancer Therapy

Video   Apr 23, 2015

 




About the Speaker
Asier Unciti-Broceta is a group leader of the Edinburgh Cancer Research UK Centre (University of Edinburgh). His research group is interested in the interface of chemistry and biomedicine, particularly on the development of novel chemical approaches for anticancer drug discovery. He is a member of the RSE Young Academy of Scotland and serves as Associate Editor of Frontiers in Chemistry (Medicinal and Pharmaceutical Chemistry specialty) since 2013. Among his awards highlight being recipient of the Nexxus (East) Young Life Scientist Award of 2010 and the RSC Young Industrialist Award of 2012.Abstract
The goal of performing bio-independent syntheses in biological environs, so called bioorthogonal chemistry, has inspired the search for novel biocompatible organic reactions for more than a decade and found a niche application as a labelling strategy to study biomolecules in their native state . While metal-free bioorthogonal reactions are considered optimal for living systems due to their biocompatibility, significant progress has been made in recent years by our group and others in the development of cell-tolerated bioorthogonal organometallic (BOOM) reactions, opening up new avenues for the exploitation of the bioorthogonal paradigm. However, the potential of such selective processes in medicine is yet to be determined. Based on the biocompatibility of metallic palladium (widely used, e.g., in dental restoration and jewelry) and its remarkable catalytic properties, our group investigates the use of heterogeneous palladium catalysis to enable site-specific conversion of cytotoxic prodrugs into its active form. As opposed to biolabile prodrugs, whose activation process relies on metabolic pathways, an efficient Pd0-activated prodrug therapy would be entirely dependent on the distinct catalytic properties of this metal and therefore the prodrug would remain intact in the absence of a Pd0 source. In this talk I will present the discovery of two palladium-mediated deprotections that take place under biocompatible conditions and their application as masking methods to suppress the activity of chemotherapeutic drugs, while enabling the bioorthogonal rescue of the drugs’ pharmacological properties by heterogeneous palladium chemistry in cancer cell culture.

 
 
 
Advertisement
 

Recommended Videos

How Fast Can a Vaccine Be Made?

Video

When a new pathogen emerges, our bodies and healthcare systems are left vulnerable. And when this pathogen causes the outbreak of a pandemic, there’s an urgent need for a vaccine to create widespread immunity with minimal loss of life. So how quickly can we develop vaccines when we need them most?

WATCH NOW

TSE Explores Drug Discovery – Testing a Drug Compound: Clinical Trials

Video

In this episode we speak with Dr Stephen Wright, Consultant in Medicines Development from Limber Strategic, who talks to us about the clinical development of a drug, including how clinical trials are designed and the role of regulatory authorities in the process.

WATCH NOW

HopkinsMedLIVE: Bias From Bench to Bedside

Video

There is a history of unequal access to health care for many groups. In this live panel discussion, Johns Hopkins scientists discuss bias in medicine and address what can be done to give everyone the opportunity to live a healthy life.

WATCH NOW

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE